This site is intended for healthcare professionals

The Lancet publishes detailed vosoritide phase III data demonstrating statistically significant increase in annualized growth velocity (AGV) over 52 weeks in children with achondroplasia.- BioMarin

Read time: 3 mins
Last updated:28th Jun 2021
Published:9th Sep 2020
Condition: Achondroplasia
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest